Omnicell (OMCL)
(Delayed Data from NSDQ)
$29.31 USD
+0.02 (0.07%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $29.55 +0.24 (0.82%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OMCL 29.31 +0.02(0.07%)
Will OMCL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for OMCL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OMCL
Omnicell (OMCL) Expected to Beat Earnings Estimates: Should You Buy?
Omnicell (OMCL) Banks on Product Launches, Global Growth
OMCL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Omnicell (OMCL) Should be in Your Portfolio Now
Why Is Inspire (INSP) Down 7.3% Since Last Earnings Report?
Omnicell (OMCL) Gains From New Offerings Amid Cost Woes
Other News for OMCL
3 Russell 2000 Stocks to Buy at a 52-week Low in July
Small and Mid-Cap stocks likely to beat/miss this earnings season - BofA
Omnicell to Release Second Quarter 2024 Financial Results on August 1, 2024
Analysts Conflicted on These Healthcare Names: Repare Therapeutics (RPTX), Omnicell (OMCL) and Oscar Health (OSCR)
OMCL Crosses Above Average Analyst Target